| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Departments of Pharmacology (E.-L.M., S.D.S., D.d.B.) and Medicine (P.H.), University of Montreal Hospital (CHUM) Research Center, Montreal, Quebec, Canada.
Correspondence to Denis deBlois, Department of Pharmacology, University of Montreal Hospital (CHUM) Research Center, 3840 St-Urbain St, Rm 7-132B, Montreal, Quebec H2W 1T8, Canada. E-mail denis.deblois{at}umontreal.ca
| Abstract |
|---|
|
|
|---|
Key Words: caspase apoptosis aorta hypertrophy hypertension
| Introduction |
|---|
|
|
|---|
The spontaneously hypertensive rat (SHR) is a genetic model of primary hypertension showing dysregulations of cell proliferation and death contributing to increased vascular mass and DNA content.7 We first reported that smooth muscle cell (SMC) death is enhanced transiently during the regression of aortic hypertrophy in SHR treated with antihypertensive agents, an effect that is not secondary to blood pressure reduction.R8-126735 8,9 Within 1 week of treatment with an antagonist of type 1 (AT1) receptors for angiotensin II, SHR aortic DNA fragmentation is maximally increased.R8-126735 8,9
The present study explored the causal relationship between SMC apoptosis and vascular remodeling induced by AT1 antagonist treatment. We first determined the relative time course of blood pressure reduction, SMC apoptosis, and aortic mass regression in SHR treated with losartan. Second, z-VAD-fmk was administered in vivo in an attempt to block losartan-induced cell death and vascular mass regression. The results suggest that caspase-dependent SMC death plays an obligatory role in onset aortic remodeling induced by AT1 receptor blockade in hypertension.
| Materials and Methods |
|---|
|
|
|---|
Time Course Study
In order to assess the time-course of losartan effects, SHR received losartan (30 mg/kg per day; gift of Merck-Frosst, Montreal, Canada) dissolved in the drinking water for 0, 4.5, 5.5, 6.5, 7.5, or 9.5 days (n=6 per group). In the subset of rats killed at day 9.5 of losartan treatment, systolic blood pressure was evaluated by tail-cuff plethysmography, as we described previously,8 on each day between days 0 and 7 of treatment.
In order to evaluate vascular DNA synthesis in vivo at 1.5 hour before death, all rats received a single intravenous bolus of [3H]-thymidine (0.5 mCi/kg; New England Nuclear) after induction of anesthesia with a single IM injection of a mixture of ketamine (80 mg/kg; MTC Pharmaceuticals), xylazine (4 mg/kg; Bayer), and acepromazine (2 mg/kg; Ayerst). Death was induced by exsanguination with retrograde perfusion of isotonic saline (200 mL) through the abdominal aorta and draining via the jugular vein. The thoracic aorta was isolated, cleaned of adherent tissue, and a vascular segment between the third and fourth intercostal arteries was fixed in 4% paraformaldehyde for histological studies. The distal segment of the aortic media (between the fourth intercostal arteries and the diaphragm) was denuded of endothelium, snapped frozen and pulverized in liquid nitrogen using a mortar and pestle and stored at -80°C.
Histological Studies
Detailed histological methods are described in the online data supplement.
Determination of Smooth Muscle Cell Number
SMC number per unit length was determined as we previously described using the 3-dimensional disector method, a quantification procedure independent of nucleus orientation, shape, or size.10 Detailed formulae are described in the online data supplement. Calculations were performed in parallel to evaluate SMC number per unit length for each animal. Final values as well as intermediate values at selected steps of the calculations (averaged for each experimental group) are presented (Table).
|
Expression of Apoptosis-Regulatory Proteins
The protein levels of the latent caspase-3 fragment (32 kDa), active caspase-3 fragments (17 to 20 kDa), active caspase-9 fragment (38 kDa), as well as Bcl-2 and Bax in the aortic media were examined by immunoblot analysis. The distal segment of the aortic media was pulverized in liquid nitrogen using a mortar and pestle, and an aliquot (25 mg) of the pulverized tissue was lysed in extraction buffer [10 mmol · L-1 Tris-HCl pH 7.5, 1% Triton x-100, 4 mmol · L-1 ßglycerophosphate, 4 mmol · L-1 sodium fluoride, 1 mmol · L-1 EDTA, 1 mmol · L-1 EGTA, 200 µmol · L-1 sodium orthophosphate, 51 µmol · L-1 benzamidine, 0.5 mmol · L-1 phenylmethylsulfonylfluoride (PMSF), 21 µmol · L-1 leupeptin, 5 mmol · L-1 DTT and 1 µmol · L-1 microsystin (Sigma-Aldrich Canada Ltd)]. Protein concentrations were determined with the Bio-Rad Assay (Bio-Rad Laboratories). Equal amounts of proteins (25 µg) separated on 15% SDS-polyacrylamide gel were transferred to Hybond-C extra membrane (Amersham, Bioscience). Membrane were blocked in 5% nonfat milk and incubated with anti-caspase-3 (1:1000 BD Pharmingen), anti-active caspase-9 (1:1000; New England Inc), anti-Bax (1:1000 Santa-Cruz Biotech), or anti-Bcl-2 (1:1000 Sata-Cruz Biotech) followed by incubation with goat anti-mouse or goat anti-rabbit horseradish peroxidase-conjugated antibody (1:2000 Santa-Cruz Biotech) and then enhancement medium ECL Plus (Life Science Products) according to manufacturers protocol. Intensity of each band was quantified using NIH Image program 1.61.
Caspase Inhibitor Study
In order to assess the role of caspases in losartan-induced vascular remodeling, male SHR (250 to 275 g) were randomized to treatment with placebo (n=15) or losartan (30 mg/kg per day; n=23) in the drinking water for 6 days. At 24 hours before death, a subset of losartan-treated animals (n=12) was randomly selected for treatment with the caspase inhibitor z-VAD-fmk (cumulative dose: 4.4 mg/kg; Enzyme System Products) given fractionally in three intravenous injections at 24, 16, and 8 hours before death. All other rats received the DMSO vehicle (100 µL per intravenous bolus) according to the same administration schedule (final group size was n=15 in placebo group, n=12 in losartan group, and n=11 in losartan+[z-VAD-fmk] group). Animals were subjected to brief anesthesia with inhalation enflurane, and the right femoral vein was exposed for the intravenous injections.
Tissue isolation procedures were exactly as described above, including [3H]-thymidine administration at 1.5 hours before death by exsanguination in anesthetized animals, and sampling of vascular sections for histological studies. In this study, 25 mg of the frozen aortic media was used as a source of material to examine both synthesis ([3H]-thymidine incorporation) and internucleosomal fragmentation of vascular DNA.
The internucleosomal DNA fragmentation index was quantified as we previously described.8 Briefly, after terminal deoxynucleotidyl transferase-mediated dUTP-[P32] nick end labeling of extracted DNA, increasing amounts of DNA (0.05 to 0.4 µg) were fractionated by 1.5% agarose gel electrophoresis. Radioactivity associated with small DNA fragments (from 150 to 1500 bps) was evaluated with a PhosphoImager (Molecular Dynamics). An aliquot of the pulverized aortic media (10 mg) from the distal segment of the vessel (between the fourth intercostal arteries and diaphragm) was lysed and DEVDase (caspase-3like) activity was measured using the fluorogenic substrate Ac-DEVD-AMC (40 µmol · L-1) (BioMol Research Labs Inc) in the presence or absence of the caspase-3 inhibitor DEVD-CHO (1 µmol · L-1), as we previously described for cultured SMCs.11 Fluorescence was calibrated with AMC (10 to 100 nmol · L-1). Caspase-3like activity was defined as the DEVD-CHO-sensitive activity.
Statistical Analysis
Values are presented as mean±SEM. Results were analyzed using analysis of variance followed by unpaired Students t test with Bonferroni correction for multiple comparisons. A value of P<0.05 was considered statistically significant.
An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
| Results |
|---|
|
|
|---|
|
As shown in Figure 2, treatment with losartan induced abrupt changes in aortic cellularity and mass. Whereas the aorta showed no change in SMC number or CSA at 4.5 days of treatment, the vessel showed a marked reduction in SMC number (46%) and CSA (8.5%) after an additional 24 hours of treatment (at 5.5 days), as measured between the third and fourth intercostal arteries. Medial CSA was 0.472±0.006 mm2 at day 0 and 0.464±0.004 mm2 at day 4.5 (NS versus day 0), whereas it was 0.432±0.007 mm2 at day 5.5 (P=0.0007 versus day 0; n=6 per group). No further significant modification of vascular cellularity or mass was observed throughout the rest of the 9.5-day treatment. Total DNA extracted from the distal segment of the thoracic aorta showed a decrease that reached significance at day 6.5 (1.09±0.05 µg/mm) as compared with day 0 (1.464±0.06 µg/mm) with no further reduction up to 9.5 days of treatment (Figure 2C). Overall, the decrease in aortic DNA correlated significantly with the depletion of SMCs (P=0.001; R=0.76). The time course of aortic SMC depletion suggested transient SMC apoptosis induction, as we previously reported.R8-126735 8,9 Consistent with this, the number of TUNEL-positive nuclei in the aortic media was markedly elevated (19-fold) at 4.5 days (Figures 2D and 3D). At that time, there was not a detectable change in vascular mass or SMC number. The increase in TUNEL-positive SMC nuclei at 4.5 days preceded the reduction of aortic cellularity and hypertrophy by at least 24 hours, and it decreased gradually over the rest of the treatment period (Figures 2D and 3F). Western blot analysis and quantification of caspase-3 cleavage fragments (17 to 20 kDa) in aortic protein extracts suggested a transient increase (5.6-fold at day 4.5) in active caspase-3 as compared with control group (Figure 4A). There was no alteration in procaspase-3 (32 kDa) expression levels (Figure 4A). Likewise, quantification of caspase-9 cleavage fragments (38 kDa) suggested a transient increase (3.8-fold at day 5.5) in active caspase-9 as compared with control group (Figure 4B). The similarities between the kinetics of activation for caspase-3 and -9 and the induction of SMC death in response to losartan suggested a possible role for caspases in this model. Further evidence for the transient induction of SMC apoptosis was provided by the increased levels of proapoptotic protein Bax (>2-fold) at days 4.5 and 5.5 (significant at 5.5 days only; P=0.007; Figure 4C) but not thereafter, and by the decreased levels of antiapoptotic protein Bcl-2 (50%) at 4.5 days but not thereafter (Figure 4D) As a result, the Bax to Bcl-2 ratio was significantly increased (>4-fold) at day 4.5.
|
|
|
In summary, antihypertensive treatment with losartan in SHR elicited an abrupt profile of vascular mass regression that was associated temporally with caspase activation and SMC deletion.
Caspase Inhibitor Study
To validate the implication of caspase-dependent cell death in the early phase of vascular hypertrophy regression in this model, the caspase inhibitor z-VAD-fmk was administered to SHR during the last 24 hours of a 6-day losartan-treatment. This schedule of z-VAD-fmk administration was selected based on data obtained using tissue extracts from the distal segment of the thoracic aorta in the time course study, which suggested recruitment of several apoptosis pathways (activation of caspase-3 and -9, increased Bax levels, and a decrease in DNA content) around day 5.5 of losartan treatment (Figures 2D and 4A through 4C). Subsets of age-matched SHR (n=3 per experimental group) were used for hemodynamic monitoring by telemetry during the 24-hour period covering the three intravenous injections of z-VAD-fmk or DMSO vehicle. As shown in Figure 5, systolic blood pressure, diastolic blood pressure, and heart rate showed no significant alteration during this period.
|
As compared with vehicle, losartan increased internucleosomal DNA fragmentation 2-fold (P=0.026), an effect that was attenuated by z-VAD-fmk (Figure 6). The results obtained using a fluorogenic caspase substrate provided additional evidence of increased caspase-3 activity (>3-fold) in aortic protein extracts after losartan treatment and confirmed the effectiveness of z-VAD-fmk as a caspase inhibitor in our in vivo model (Figure 7A). Consistent with the time course data described above, treatment with losartan for 6 days caused a significant reduction in aortic SMC number (47%), medial CSA (11%), and media DNA content (20%) (Figure 7). All these effects of losartan were suppressed by z-VAD-fmk (Figure 7). As a further confirmation that z-VAD-fmk suppressed vascular mass regression, the aorta to body weight ratio showed a significant 16% reduction with losartan (4.1±0.2 mg/mm per gx10-3; P=0.007) as compared with control values (4.9±0.2 mg/mm per gx10-3), a change that was prevented by z-VAD-fmk (5.0±0.1 mg/mm per gx10-3; P=0.0001). The incorporation of [3H]-thymidine into aortic DNA was not significantly affected with losartan (93±9 CPM/10 µg; NS) or by z-VAD-fmk (85±9 CPM/10 µg; NS), as compared with control values (106±19 CPM/10 µg).
|
|
In summary, a caspase inhibitor prevented the early regression of vascular hypertrophy and hyperplasia induced by losartan without affecting hemodynamic parameters.
| Discussion |
|---|
|
|
|---|
SMCs have been shown to act as amateur phagocytes in the presence of apoptotic bodies in vitro.12 In rabbit carotid arteries undergoing remodeling in response to reduction in flow, Cho et al13 reported that removal of apoptotic SMCs occurred with a half-life of 1 to 2 hours in vivo. However, the estimated frequency of apoptotic SMC in the rabbit arteries (0.13%) was lower than in the present study (approximately 30%). We noted that the magnitude of SMC depletion, assessed histologically, was slightly larger than the significant reduction of total vascular DNA, possibly reflecting incomplete removal of remnant apoptotic bodies in the arterial wall. Consistent with this, we reported that after 4 weeks of losartan treatment in SHR, the decrease in aortic DNA content is comparable (or slightly greater) that the decrease in SMC number.8 It may be relevant that SMC nuclear profiles and total DNA content were quantified in different aortic segments (proximal and distal to the heart, respectively). In the early phase of vascular regression, the incidence of SMC apoptosis may be lower or slower to develop at the more distal levels of the thoracic aorta. The formation of polyploid SMC by nuclear fusion may also reduce the number of SMC nuclear profiles. Although it cannot be formally excluded, we consider this possibility unlikely because of the low incidence (
1%) of multinucleated SMC in 3-month-old SHR aorta.14 Moreover, the enhanced accumulation of polyploid SMC in the untreated SHR aorta14 is reversedR15-126735 15,16 rather than increased by AT1 receptor antagonists.
In other acute in vivo models of apoptosis induction such as in rat ischemic cardiomyocytes, Fas-stimulated mouse hepatocytes, and ischemic mouse neurons, z-VAD-fmk effectively inhibits apoptosis with preservation of functionality in the later two models.R4-126735 R5-126735 46 The plasma z-VAD-fmk concentration likely reached in the present study (25 µmol/L range) is in the lower range of the concentrations used in vitro to inhibit caspases.2 Moreover, inhibition of ischemic cardiomyocyte apoptosis in vivo is dose-dependent in the range of the z-VAD-fmk dose used in the present study.17
Previous studies suggested that transient induction of SMC apoptosis was a common feature of aortic hypertrophy regression in SHR treated with different classes of antihypertensive drugs, including AT1 antagonists, angiotensin converting enzyme inhibitors, and dihydropyridine calcium channel blockers.R8-126735 8,9 These drugs also induce a transient increase in cardiac apoptosis during regression of cardiac hypertrophy,18 a response that results in selective reversal of fibroblast hyperplasia in the SHR heart.19 Evidence suggest that apoptosis is also increased by losartan treatment in small mesenteric arteries of SHR, although with a delayed kinetic of induction.20 Nifedipine treatment increases SMC apoptosis and reduces SMC number in the carotid artery neointima of SHR and of Wistar-Kyoto rats but not in the underlying media.21 The possible role of blood pressure reduction in SMC apoptosis induction during aortic mass regression is worth considering. Arterial unloading and reduction in blood flow can induce SMC apoptosis.R13-126735 R22-126735 R23-126735 13,2224 In vitro studies have established, however, that angiotensin II can modulate SMC apoptosis negatively (via AT1 receptorsR25-126735 25,26) or positively (via AT2 or AT1 receptors27) in the absence of hemodynamic influences. In SHR treated with the AT1 antagonist valsartan, coadministration of the AT2 antagonist PD123319 prevents both SMC apoptosis and vascular mass regression, although it does not affect blood pressure reduction.9 Moreover, treatment with the angiotensin converting enzyme inhibitor enalapril for one week markedly reduces blood pressure without affecting SMC apoptosis at that time in the SHR aorta.8 Likewise, marked reduction of high blood pressure with hydralazine is not associated with vascular apoptosis or remodeling within 4 weeks in SHR.8 In the present study, the decline in high blood pressure over the first week of losartan treatment contrasted with the sudden onset and subsequent stabilization of SMC deletion and regression of vascular mass. Collectively, these data suggest that the regulation of SMC apoptosis and early vascular mass regression in this model show a strong pressure-independent component, although a role for hemodynamic factors cannot be formally excluded. It is however important to note that z-VAD-fmk suppressed apoptosis without affecting key hemodynamic parameters in SHR.
The time-dependent changes in apoptosis-related proteins suggest that caspase-3 activation and bcl-2 downregulation acted upstream of Bax and caspase-9. After a death signal, Bax can associate with the mitochondria to induce the release of cytochrome c and formation of the apoptosome complex in association with caspase-9 activation.R28-126735 28,29 The signaling pathways responsible for cell death in the present model remain incompletely defined, but evidence suggest a role for AT2 receptors for angiotensin II.9 In recent years, it has become apparent that angiotensin II modulates apoptosis in a cell type and receptor subtypedependent manner. Acting via AT1 receptors, angiotensin II can suppress apoptosis in SMCs but stimulate apoptosis in endothelial cells and cardiomyocytes.R27-126735 27,30 AT2 receptors can however induce apoptosis in SMCs, endothelial cells, cardiomyocytes, and cardiac fibroblasts.R27-126735 27,31 AT2 receptor-dependent apoptosis is associated with Bcl-2 downregulation and executioner caspase-3 activation.R27-126735 R32-126735 27,32,33 Other key intracellular pathways implicated in mediating AT2-dependent apoptosis include de novo ceramide generation and protein phosphatase activation.R27-126735 27,33 In vivo, the role of AT2 receptors is more controversial.R34-126735 R35-126735 R36-126735 3437 With its rapid kinetics, the present in vivo model provides a framework for studying the molecular regulation of AT2 receptor- and caspase-dependent SMC death during onset vascular remodeling with AT1 receptor antagonists in hypertension. To our knowledge, this model currently exhibits one of the largest synchronized induction of cell death by apoptosis in vivo. Massive cell death by apoptosis in vivo has been described in pathological conditions such as postangioplasty vascular remodelingR38-126735 38,39 and Fas-induced liver degeneration in mice.6 Considering the current focus on inhibitors of apoptosis as potential therapeutic agents, it is noteworthy that apoptosis may be viewed as therapeutically beneficial in the present model.
Some limitations of the present study should be addressed. First, the relative role of caspase subtypes remains to be determined because z-VAD-fmk is not specific for caspase subtypes. Second, long-term effects of caspase inhibition on SMC survival are unknown. Although apoptosis inhibition with z-VAD-fmk maintains functionality in ischemic hepatocytes, neurons, and cardiomyocytes in vivo, other in vitro studies have shown that apoptosis inhibition may eventually lead to noncaspase-dependent cell death.40 Third, nonspecific effects of z-VAD-fmk, for instance on lysosomal cysteine proteases of the cathepsin family, cannot be ruled out.41 The role of cathepsins in apoptosis is unclear, with studies in nonvascular cells showing stimulation, suppression, or no effect.R42-126735 R43-126735 4244 Cathepsin-induced apoptosis may involve a limited caspase-processing activity.45 Overall, available evidence suggests that caspases act downstream of cathepsin-mediated apoptosis.R46-126735 46,47 Whatever the relationship between caspases and cathepsins, the present conclusion that SMC apoptosis inhibition prevents early vascular mass regression with an AT1 antagonist is supported by our previous study in SHR cotreated with an AT2 receptor antagonist.9
In summary, the early phase of aortic mass regression in losartan-treated SHR occurred as an acute and rapid event synchronized with a transient increase in Bax to Bcl-2 ratio, caspase-3 activation, and SMC apoptosis. Caspase inhibition with z-VAD-fmk prevented losartan-induced apoptosis and regression of aortic hypertrophy. Together these results demonstrate that caspase-dependent SMC death mediates the early phase of vascular remodeling in response to AT1 receptor blockade in this rat model of essential hypertension.
| Acknowledgments |
|---|
Received May 15, 2002; revision received November 6, 2002; accepted February 26, 2003.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Westaby, G. B. Bertoni, C. Clelland, T. Nishinaka, and O.H. Frazier Circulatory support with attenuated pulse pressure alters human aortic wall morphology J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 575 - 576. [Full Text] [PDF] |
||||
![]() |
M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Igase, W. B. Strawn, P. E. Gallagher, R. L. Geary, and C. M. Ferrario Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1013 - H1019. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dutil, V. Eliopoulos, E.-L. Marchand, A. M. Devlin, J. Tremblay, K. Prithiviraj, P. Hamet, A. Migneault, D. deBlois, and A. Y. Deng A quantitative trait locus for aortic smooth muscle cell number acting independently of blood pressure: implicating the angiotensin receptor AT1B gene as a candidate Physiol Genomics, May 11, 2005; 21(3): 362 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Levy Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin-Angiotensin System Circulation, January 6, 2004; 109(1): 8 - 13. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |